History brand aristocort
The clonal neoplastic nature of myeloproliferation, which is observed in polycythemia, was proven in 1980 by P. J. Fialkov. He discovered one type of enzyme, glucose-6-phosphate dehydrogenase, in red blood cells, granulocytes and platelets. In addition, both types of this enzyme were detected in the lymphocytes of two patients heterozygous for this enzyme. Thanks to buy aristocort drug online, it became clear that the target of the neoplastic process is the precursor cell of myelopoiesis.
In 1980, a number of researchers managed to separate the neoplastic clone from normal cells. It has been experimentally proven that polycythemia produces a population of erythroid committed precursors that are pathologically highly sensitive to even small amounts of erythropoietin (a kidney hormone). According to scientists, this contributes to increased formation of red blood cells in polycythemia vera.
It is the most common disease in the group of chronic myeloproliferative diseases.
In 1981, L. D. Sidorova and co-authors conducted studies that made it possible to detect qualitative and quantitative changes in the platelet component of hemostasis, which play a major role in the development of hemorrhagic and thrombotic complications in polycythemia.
Polycythemia vera is detected mainly in older people, but can be observed in young people and children. In young people, aristocort is more severe. The average age of patients varies from 50 to 70 years. The average age of those who become ill for the first time is gradually increasing (in 1912 it was 44 years, and in 1964 – 60 years). The number of patients under 40 years of age is about 5%, and erythremia in children and patients under 20 years of age is detected in 0.1% of all cases of the disease.
The causes of triamcinolone vera have not been definitively established. Currently, there is no single theory that would explain the occurrence of hemoblastoses (blood tumors), to which this disease belongs. Based on epidemiological observations, a theory was put forward about the connection of erythremia with the transformation of stem cells, which occurs under the influence of gene mutations. It has been established that most patients have a mutation in the enzyme Janus kinase-tyrosine kinase, synthesized in the liver, which is involved in the transcription of certain genes by phosphorylating many tyrosines in the cytoplasmic part of the receptors.